Sumitomo Pharma America
NEWS
Myovant’s oral Orgovyx beat out Abbvie’s injectable Lupron in achieving medical castration levels in patients. Here is the timeline of the approval.
It was another busy week for clinical trial updates and news. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
It was a busy week for clinical trial updates. Here’s a look.
Relugolix is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist.
The company presented the data at the American Society of Clinical Oncology Virtual Scientific Program and also published data simultaneously in the New England Journal of Medicine.
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
This morning, the Switzerland-based company said its SPIRIT-2 study met its co-primary efficacy endpoints and six key secondary endpoints for endometriosis treatment.
It was a very busy week for clinical trial news. Here’s a look.
JOBS
IN THE PRESS